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Objective: The current article is aimed at identifying the best practice for counseling around
depression in community and outpatient pharmacies, resulting in a draft guideline, proposing key
steps and an algorithm for integration of community pharmacists into care for patients with
depression.
Methods: A literature review was performed followed by a detailed analysis, for the
purpose of creation a short draft document used as a basis for creation of a guideline for
pharmaceutical care for patients with depression. The technological scheme PRISMA flow
diagram was applied. The paper is based on current knowledge, taking into consideration
already published articles, guidelines, and recommendations about pharmaceutical care for
patients with depression, giving a basis for further studies.
Results: This paper includes two main sections: 1) depression – a short description of the
main symptoms, risk factors and pharmacotherapy guidelines available in Bulgaria important
for the purposes of ensuring qualitative community-based pharmaceutical care; and 2) the
pharmacists’ role in providing high-quality care – the main aspects of pharmaceutical care
for patients with depression with specific examples.
Conclusion: The involvement of pharmacists in supporting depressive patients is crucial
taking into account the specific characteristics of the pharmacological treatment: delayed
onset of clinical results, risks in case of sudden pharmacotherapy abruption without physi-
cian consultation, multiple adverse drug reactions and drug–drug, drug–food and drug–
alcohol interactions, etc. The current article could also be used as an initial document for
creating a methodological guideline for providing pharmaceutical care services for patients
with depression.
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Background
Pharmaceutical care is a responsible provision of drug therapy for the purposes of
achieving definite outcomes and improvement of patient’s quality-of-life.1 The main
responsibilities of the pharmacists are defined as a result of long-term studies: 1) to
ensure that all medications are appropriate, effective, and safe for a particular patient,
and 2) to identify, solve, and prevent various drug-related problems (DRPs).2 In 2013
a working group formed by investigator members of the Pharmaceutical Care Network
Europe (PCNE) preformulated the definition so as to respond to the current expecta-
tions and views: “Pharmaceutical Care is the pharmacist’s contribution to the care of
individuals in order to optimize medicines use and improve health outcomes”.3
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Depression is a common psychiatric illness, which is
associated with several specific symptoms such as
depressed mood, markedly diminished interest or plea-
sure in activities, psychomotor retardation, weight loss
or weight gain, fatigue or loss of energy, feelings of
worthlessness or guilt, recurrent thoughts of death, or
recurrent suicidal ideation, etc.4 Being chronic in nature
and affecting people of working age, depression leads to
great economic and financial burden, which is also eval-
uated in a number of studies.5,6,7 Moreover, the World
Health Organization (WHO) reports that depression will
be the second leading cause of disability in the world by
2020.8 Non-adherence to antidepressants, which is
defined as being over 75% after 6 months, could lead
to a lack of effect, to higher costs and significant burden
for the patient, family, and society.9
Pharmacists may play a significant role in the primary care
for patients suffering from depression, giving advice, recom-
mendations, counseling about medicines, following up the
patients for drug-related problems, and assessing patients’
adherence on the basis of their skills and knowledge about
the medicines.10 The community pharmacist is recognized as
a crucial member of the multidisciplinary primary care team
for all patients with chronic and acute diseases.11 Pharmacist-
provided patient care services are proved to bring significant
benefits on patient health outcomes.12 Gomes et al13 evaluated
the effectiveness of pharmaceutical care services and their
influence on the patients’ quality-of-life. As a result of ensur-
ing various interventions for increasing the level of compli-
ance and educational programs, the depressive symptoms
were reduced and the quality-of-life was improved
(P<0.05). Another study among patients with depressive dis-
order demonstrated quality-of-life improvement, improved
adherence, and effectiveness of the therapy as a result of
pharmaceutical care services.14 In comparison with the stan-
dard care, pharmaceutical care provides a reduction in the
number of hospitalizations and emergency visits not only
in patients with depression, but also in patients with
bipolar disorder.15 Rubio-Valera et al9 found a probability of
0.71–0.75 for community pharmacy intervention vs usual care
in depressed patients initiating treatment in terms of improved
adherence level and Quality Adjusted Life Years (QALYs) to
be cost-effective.
Searching in the literaturewe identified only reviewpapers,
a pharmacist guided protocol for improved of monitoring
patients treated with antidepressants, and physician-focused
clinical practice guidelines or some local implemented instruc-
tions regarding pharmaceutical services for this group of
patients.16,17,18,19 In 2018, the Royal Pharmaceutical Society
highlighted the need for implementing the pharmacists’ poten-
tial for supporting people with mental disorders without pre-
senting any specific and concrete guidance.20 Moreover, the
role of the pharmacists and their unique skills in medication
management, provision of drug information, and counseling
patients with mental diseases is clearly identified in a recent
study by Rubio-Valera et al.21 Therefore, pharmacists all
around the world need a detailed guideline providing algo-
rithms and instructions on how and when pharmaceutical care
should be provided to patients with depressive disorders.
The current article aimed at identifying the best practice for
counseling around depression in community and outpatient
pharmacies, resulting in a draft guideline, proposing key
steps and algorithms. The article gives a short description of
the main symptoms, risk factors, and pharmacotherapy guide-
lines important for the purposes of ensuring qualitative com-
munity-based pharmaceutical care for patients with
depression. It also highlights the pharmacists’ role in providing
a high-quality care presenting the main aspects of pharmaceu-
tical care for patients with depression presenting the most
common identifiable drug-related problems among the
observed group of patients.
Methods
A literature review of the published literature regarding phar-
maceutical care, depression treatment, and role of the phar-
macist in the care for patients with depressive disorder was
performed. A detailed analysis for the purpose of creating
a short guideline for pharmaceutical care for patients with
depression was made. The discussion about the guideline’s
structure and further validation of the drafted guideline are
planned to be the next steps. The paper is based on the current
knowledge taking into consideration already published arti-
cles, guidelines, and recommendations about pharmaceutical
care for patients with depression.
A search was conducted in the Internet based scientific
data base PubMed as well as in other sources, such as paper-
based journals and scientific books. The keywords used were
depression, pharmaceutical care, pharmacists, and pharmacy
services. A particular consistency was followed:
1. Defining the study question: What are the best prac-
tices for counseling around depression in commu-
nity and outpatient pharmacies?
2. Input the key words in the database PubMed Clinical
Queries – “depression” AND “pharmaceutical care”
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OR “pharmacy services “AND “pharmacists” AND
“community pharmacy” OR “outpatient pharmacy”.
3. Other relevant sources of information were also
reviewed, and suitable studies were selected.
4. The search for the available studies in PubMed
was initiated and the details shown by the system
were subdivided into three categories: clinical
studies, systematic reviews, and medical genetics.
5. The studies were analyzed following the PRISMA
flow diagram. The duplicated studies were with-
drawn from the analysis. Studies were selected
only if they met the following inclusion criteria: 1)
The studies were free full text systematic reviews,
government documents, reports, comments, classi-
cal articles, or guidelines; 2) The objects in the
studies were patients with depression (no limitation
regarding the age); 3) Studies were in English;
and 4) Studies including specific drug-related pro-
blems and ways for overcoming and preventing
them. The exclusion criteria were: 1) duplicated
studies; 2) language different from English; 3) stu-
dies focusing mainly on efficacy of specific thera-
pies for depression; and 4) studies which covered
patients who did not suffer from depression but
from other mental disorders;
6. The technological scheme PRISMA Flow Diagram
was applied.
Results and Discussion
There were 77 papers relevant to our research question: 47 in
PubMed and 30 from other sources (books, paper-based
reports, guidelines, and articles). The study selection process
is presented in Figure 1. No potentially relevant studies after
duplicates were removed. After reviewing the titles, abstracts,
and the full publications, 39 of the articles meeting exclusion
criteria were excluded and only 38 were summarized.
The characteristics of the included studies are initially
analyzed, summarized, and combined for the purposes of
presenting initial ideas for creating a guideline. They are
presented in the current part of the article as we are
planning to present a discussed and validated version of
the guideline in a further more detailed paper.
Depression – Symptoms, Epidemiology,
and Treatment
Depression is a common psychiatric disorder affecting
more than 300 million people worldwide. It causes
significant distress, limitations in personal and social
functioning, and worsens the quality-of-life of
those affected.22,23 The Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5) out-
lines specific criteria for the diagnosis of depression.
Some of the most specific symptoms are depressed
mood, loss of interest or pleasure, significant weight
loss or weight gain, a slowing down of thought and
a reduction of physical movement, fatigue or loss of
energy, feelings of worthlessness or excessive or inap-
propriate guilt, diminished ability to think or concentrate,
recurrent thoughts of death or suicidal thoughts.24,25
Among all mental disorders, depression is related to the
highest risk of suicide, followed by schizophrenia and
alcohol abuse.26 The main causes for depression are
genetic factors, personal predisposition, concomitant dis-
eases, family history, huge life changes (negative or
positive events), or social determinants (stress, isolation,
loneliness, unemployment).27 Depression might be in
mild, moderate, or severe form, which is defined after
complex clinical evaluation based on the number, type,
and severity of the symptoms. According to the mono-
amine hypothesis, depression is characterized by dimin-
ished activity of monoamine neurotransmitters
(predominantly norepinephrine, dopamine, and serotonin)
in the brain. The amygdala, the thalamus, the hippocam-
pus, and the prefrontal cortex play significant roles in
depression, where the low levels of monoamines cause
the symptoms of dysthymia, anhedonia, lack of motiva-
tion, lack of activity, fatigue, insomnia, and cognitive
effects. Depression is associated with chronic stress,
which overactivates the hypothalamic–pituitary–adrenal
axis, causing elevated levels of cortisol, induction of
fight-or-flight response, and overactivation of the autono-
mous nervous system with somatic symptoms (tachycar-
dia, palpitation, shortness of breath, and diaphoresis by
overactivation of the sympathetic nervous system and
gastrointestinal symptoms by overactivation of the para-
sympathetic nervous system). Chronic stress also changes
the immune response and causes reduced neuroplasticity.
Early losses and trauma experiences significantly increase
the risk of depression later in life through their effect on
the limbic system.28,29
Pharmacotherapeutic guidelines for treatment of psychia-
tric disorders present the main principles of depression treat-
ment on the basis of severity, age, and concomitant diseases
Dovepress Kamusheva et al
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(Figure 2). The goal of treatment is achieving remission and
full recovery of the patient’s social functioning.22
The first antidepressant (AD) was discovered in the
1950s, and several pharmacological groups are available
now: monoaminoxidase inhibitors, selective inhibitors of
serotonin reuptake (SSRIs) and/or noradrenaline (SNRIs),
tricyclic and tetracyclic antidepressants, SPARI, and -
multimodal AD (Figure 3).30,31 The first line therapies
are: SSRIs, SNRIs, and serotonin antagonist and reuptake
inhibitors (SARIs), noradrenergic, and specific serotoner-
gic antidepressant (NaSSA (mirtazapine)). Tricyclic AD,
MAOIs, and others AD (tianeptine, agomelatine
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Figure 1 PRISMA flow diagram. Adapted from: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement. PLoS Med. 6(6): e1000097. doi:10.1371/journal.pmed1000097.
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(melatonergic)) as well as some antipsychotics are indi-
cated as second line therapy.32
Pharmaceutical Care Aspects for Patients
with Depression
The pharmacist’s obligations in the process of provid-
ing pharmaceutical care are: (1) collection of specific
information for the patient’s demographic data, history
of disease, medication therapy (current therapy, dose,
therapeutic regimen, allergies, immunizations, previous
drug therapy), current complaints; (2) analyzing the
collected information so as to identify drug-related
problems, to assess whether all medications are effec-
tive and safe for the patient as well as patient’s adher-
ence and compliance.33,34 Follow-up was aimed at
defining the therapy effectiveness and long-term safety,
Monotherapy
Assessment of adverse 
effects - every week;
Initial assessment of 
therapeutic 
effectiveness - 3-4 
weeks and optimization 
of dosage regimen
Assessment of the real 
therapeutic effect - 6-8 
weeks
Lack of effectiveness
•Assessment of the 
diagnosis;
•Switch to other AD*;
•Adds on or combined 
therapies - combination 
between 2 different classes 
AD*; combination between 
AD* and antipsychotic; add 
lithium or thyroid 
hormones or vitamins or 





•At least 6-12 
months;
•Aim: to achieve full 
clinical remission and 
full recovery.
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Figure 3 Main pharmacological groups antidepressants.
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assessing clinical results, defining the level of achiev-
ing the goals, level of adherence, and reassessing of
new potential or actual DRPs (Figure 4).35
The concepts and goals of provided pharmaceutical
care could be based on the type of patient’s visit: initial
or follow-up (Figures 5 and 6).36
Communication with the Patients and Their Family
Members/Caregivers
Establishment of contact with the patient with depression,
asking appropriate questions
Communication with patients with mental problems
presents a challenge for every pharmacist. Despite the
various communication difficulties, the pharmacist should
apply innovative strategies for overcoming them.37 The
pharmacist should play the dominant role during the
conversation, applying appropriate voice tone, using sim-
ple and short sentences and body language without dis-
cussing several issues simultaneously – a focus should be
made on a specific problem through a variety of technical
and non-technical skills.38 The consulting pharmacist
should pay attention to and adapt the discussion towards
patient’s difficulties related to verbal speech and
memorization.
Assessment of the 
individual drug-related 




















Reduced level of 
compliance. 
Solve DRPs**
Define therapeutic goals 
Prevent of potential DRPs**
Intervention applicable:
Start new therapy;
Change the dosage regimen;
Change the dosage form;
Discontinuation of the treatment;
Patient education etc.
Figure 4 Steps and key element of pharmaceutical care.
Abbreviations: ADR, adverse drug reaction; DRP, drug-related problem.
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The pharmacist as a health professional is able to recognize
the initial symptoms, to identify the risky groups, and to target
vulnerable people to join supporting groups, initiate
nonpharmacological treatment, or make an appointment with
a psychiatrist for prescribing eventually of themost appropriate
pharmacotherapy. Asking open-ended and closed questions,
INITIAL VISIT
COLLECT AND ORGANIZE PATIENT SPECIFIC INFORMATION:
- demographic, administrative, medical, lifestyle, 
social/economic information
ANALYZE THE INFORMATION AND IDENTIFY THE ACTUAL AND 
POTENTIAL DRUG-RELATED PROBLEMS (DRPs)
(The effectiveness of the therapy, low or high dose, interactions, level of compliance etc.)
CONSULT THE 





EDUCATE THE PATIENTS AND GIVE CONSULTATION REGARDING THE PRESCRIBED THERAPY
- Clarify the therapeutic scheme;
- Therapy starts with lower dose, which is gradually rising;
- Clarify the mechanism of action of antidepressants using simple word;
- Admonish the patient to take the medications regularly according to physician advice;
- Explain that the onset of action is usually after 10-20 days of treatment (or longer 4-6 weeks)
- Do not stop the medications abruptly (risk of withdrawal syndrome).  It might take around 4 weeks if there is no serious ADR
- The therapeutic regimen might be longer than expected - at least 6 months after remission starts in case of first depressive 
episode OR 12 months in case of second depressive episode. In case of more than 2 episodes the therapy might be lifelong
- To avoid taking sympathomimetic (for ex. decongestants), tyramine-containing food, alcohol during the treatment with 
MAOIs and 2 weeks after that;
- How to prevent and recognize serotonin syndrome symptoms
- Avoid alcohol and tobacco consumption;
- Keep attention when driving and machine use (some AD lead to dizziness and drowsiness)
- Contact the doctor or emergency center in case of enhanced suicidal thoughts appeared in the beginning of the therapy.
CONTINUING COMMUNICATION WITH THE PATIENT
Identify patient-specific needs and concerns regarding the therapy and disease
SPECIFY THERAPEUTIC GOALS
DESIGN A SPECIFIC INDIVIDUAL THERAPEUTIC PLAN
Collaborate actively with the physician and consider patients’ needs and preferences 
DESIGN A SPECIFIC FOLLOW-UP PLAN
Consider patients’ needs and preferences;
Ensure regular visits (phone calls, visits at pharmacy etc.)
DOCUMENTING
Figure 5 Algorithm for applying pharmaceutical care for patients with depression – initial visit.
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avoiding confusing questions and interrupting patients while
he/she is speaking, listening actively, demonstrating empathy
and using the most appropriate body language (eye contact,
smile, understanding look, etc.) could help the pharmacist to
significantly improve the communication process (Table 1).
Moreover, the community pharmacists have frequent contact
with patientswith depression and othermental health problems
which gives them the possibility to engage the patients more
actively in the therapeutic process.39
Education of the Patient and His/Her Relatives/
Caregivers
GiveAdditional InformationAbout theDisease and Symptoms
As one of the most accessible health professionals, the
pharmacists could assist the risk groups (postpartum
women, geriatric patients, teenagers, etc.) to visit
a psychiatrist. Participating in community-based health cam-
paigns, assuring appropriate advice and information flyers
including suitable directions for rational drug use, clarifying
the importance of therapy adherence, nonpharmacological
treatment approaches and lifestyle modification, the pharma-
cists could not only improve community health but also
contribute in decreasing the stigma of depressive
disorders.40 Different studies confirmed the capability of
the pharmacist to be involved in screening programs and
risk assessment services for depression.41,42 Kondova et al43
identified that 70% of all patients screened in a community
FOLLOW-UP VISIT
IDENTIFY NEW DRPs AND ASSESS THE LEVEL OF 
COMPLIANCE
CONSULT THE 








GATHER INFORMATION REGARDING THE PATIENT 
NEEDS AND CONCERNS 
ASSESS PATIENT’S LEVEL OF UNDERSTANDING THE IMPORTANCE OF 
THERAPY AND PATIENT’S KNOWLEDGE REGARDING THE THERAPY
EDUCATE THE PATIENT AND IMPROVE HIS KNOWLEDGE 
REGARDING THE PRESCRIBED THERAPY  
NO
YES
REDESIGN THE THERAPEUTIC PLAN IF IT IS NECESSARY
Collaborate with the physician 
Consider patient’s preferences and DRPs
APPOINTMENT OF NEXT VISIT
DOCUMENTING
NO
Figure 6 Algorithm for applying pharmaceutical care for patients with depression – follow-up visit.
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pharmacy setting have positive results of PHQ-2 test, and
55% of them had indications of mild-to-moderate
depression. One of the possible methods for timely diagnosis
is through giving various depression screening tools (Patient
Health Questionnaire (PHQ-2 and PHQ-9), Self-Rating
Depression Scale (Zung scale (SDS)) or Von Zerssen
scale).44
A systematic review published in 2018 concluded that
educational materials, outreach visits, and feedback can
improve counseling in community pharmacy settings.45
Therefore, additional information regarding the following
topics should be given to patients with depression: what
the first signs of depression are, how important the con-
sultation with a psychiatrist is due to the risk of serious
complications, how the medications should be taken, etc.
The relatives and friends could also be involved in the
team caring for patients with depression (Figure 7).
Understanding the Principles of Non-Pharmacological
Treatment
There are a lot of nonpharmacological approacheswhich could
be implemented in the individualized care plan for depressive
patients: cognitive behavioral therapy [CBT] (the psychothera-
pist identifies irrational and dysfunctional patient’s thoughts
and looks for new more realistic ones; the purpose is to over-
come the negative thinking and to modify the existing beha-
vioral models); physical activity – 3–5 times per week,
20–30 minute nature walks, etc.; light therapy – in case of
seasonal depressive disorders; music therapy; acupuncture;
food supplements (omega 3 oils, Hypericum perforatum);
stress management practicing yoga, meditation; healthy eating
and sleeping habits; cognitive bibliotherapy.46,47,48
Assuring Effective, Safe, and Appropriate
Pharmacological Treatment
Giving Instructions about Dosage Regimen and Therapeutic
Scheme
Giving detailed guidance regarding pharmacotherapy by the
provider of pharmaceutical care, the service pharmacist, is
crucial. The educational process includes an explanation of
the therapeutic scheme, the mechanism of action of antidepres-
sant (AD), avoiding complex medical words, and clarification
that the onset of action of the prescribed AD is usually after
10–20 days (or longer: 4–6 weeks) and the therapy is contin-
uous (2–6 months) depending on the severity of the disease.
The initial dose is lower and it increases gradually. The patient
must adhere to the therapeutic scheme as long as it is prescribed
knowing that there is no risk of addiction.49 The therapy must
Table 1 Questions Asked by Pharmacists and Their Purposes
Question Purpose
What medications do you take in what dose and when do you take them? ● The purpose is to understand whether the patient understands
the prescribed therapy and administrates it properly
How long do you take these medications according to the current dosage
regimen? When was the last time your therapy was changed?
● The purpose is to clarify the effectiveness and appropriateness of
the therapeutic regimen
How do you feel after taking your medication(s)? ● The purpose is to clarify the effectiveness and appropriateness of
the therapeutic regimen
Do you consider stopping abruptly the medications for depression? Do you
think interrupting the therapy suddenly is appropriate?
● In this way the pharmacist can identify the level of patient’s knowl-
edge regarding the medications and therapeutic regimen
Do you consult with a pharmacist when buying OTC medicinal products? ● To identify timely drug-related problems
Would you like to ask some questions regarding the medications you take? ● To assess the level of knowledge and to stimulate the patient to be
an active partner in the process
Have you ever had suicidal thoughts? ● To assess the severity of the disease
● To assess the history of condition
● To indicate worsening of the condition
Do you see your psychiatrist regularly? ● To identify the level of adherence to therapy
● To identify the level of patient’s involvement in the therapeutic
process
Dovepress Kamusheva et al
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not be stopped suddenly – a period of 2–3 weeks is required.
Even if the symptoms relieve the therapy must be continued
and not stoppedwithout the physician's recommendation due to
the risk of withdrawal syndrome (irritability, headache, insom-
nia, palpitations, sweating, and others lasting several days).
Regular monitoring should be provided to every patient with
depression in order for suicidal thoughts to be identified in
a timely manner. Depressive symptoms are assessed every
week or every other week. So, the pharmacist should remind
the patient to consult with his/her physician regularly.
Identification and Prevention of Drug-Related
Problems
Understanding the Most Common Adverse Drug Reactions
(ADRs) and Giving Advice for Overcoming Some ADRs
Informing About the Possible Drug–Drug and Drug–Food
Interactions. An essential element of pharmaceutical care
services is the so-called medication review aimed to opti-
mize medicines use and improve health outcomes.50
Therefore, serious drug-related problems (DRPs) could
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If the patient 
is in severe 
depressive 
condition, he/she 
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due to the risk of 
self-injuring
Figure 7 Pharmacists’ advice for the relatives of those affected by depression.
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the prevention and overcoming of the revealed DRPs
could be recommended. PCNE developed a detailed guide-
line of DRPs, classifying them into several groups accord-
ing to the type of problems, the causes, planned
interventions for overcoming, level of acceptance, status,
etc. (Table 2). According to the causes, DRPs are related to
prescribing, dispensing, and drug use (Table 3).51
Identification and prevention of actual and potential DRPs
is one of the main tasks of the pharmacists in the process of
providing medication management services. The patient who
suffers from depression should be acquaintedwith the possible
adverse drug reactions related to the therapy with antidepres-
sants. The most frequent ADRs are dryness in mouth, tachy-
cardia, tremor, vomiting, sedation, weight gain, arrhythmias,
insomnia, skin reactions – photosensitization, reduced sexual
functions, etc. Some of them are dose-dependent and decreas-
ing over time. Tobacco consumptionmight influence the effect
of antidepressants – there are several studies showing evidence
regarding the reduction of plasma concentration of fluvoxa-
mine, duloxetine, mirtazapine, and trazodone in smokers in
comparison with non-smokers. The therapy choice should be
based on the status of the patient – whether he is a smoker
or non-smoker, due to the risk of pharmacokinetics
interactions.52 Alcohol consumption is also contraindicated
during the therapy with antidepressants. The pharmacist
should clarify that antidepressants might lead to drowsiness
and disturbances in concentration and therefore may influence
the ability to drive and use machines. The appearance or
enhancing of suicidal thoughts might be reported in the begin-
ning of the therapy with AD, but it could not be a reason for
interrupting the therapy – the patient and their caregivers
should be advised to contact their psychiatrist or emergency
center for more information.
Information regarding serotonin syndrome symptoms
(SSS) and their prevention and recognition should be
provided by the consulting pharmacist. SSS (hyper-
reflection, tremor, dizziness, parasympathetic reactions,
confusion, etc.) can be a result of simultaneously taking
serotonin agonist and serotoninergic medicinal products.24
Other DRPs which could be identified by the pharma-
cist are: lack of effectiveness of the prescribed medicines,
dose too high or too low, drug-drug, drug-food supple-
ments or drug–food interactions (Table 4), and low level of
adherence.53 The pharmacist is able to give practical
advice for overcoming ADRs reported as a result of AD
treatment (Table 5).54,55








Others (inappropriate drug, etc.)























Table 3 Classification of DRPs on the Basis of the Causes 51
Group of DRPs Examples
Related to
prescribing
Drug selection Inappropriate drug;
contraindications;
duplication of drugs; too
many drugs for one
indication, etc.
Drug form Inappropriate drug form
Dose selection Dose too low or too high;
wrong instructions for
dosing, etc.
Treatment duration Too short or too long
Related to
dispensing
Dispensing No availability of the drug;








health specialist or by the
patient)
Inappropriate time dosing;
patient abuses drug; takes
too high or too low dose;
wrong way of administration;
inability to use the drug
correctly, etc.
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Creation of Individualized Therapeutic Plan and
Defining of Specific Goals
The main therapeutic goal in patients with depression is
overcoming the symptoms with reducing as much as pos-
sible the adverse drug reactions, prevention of suicidal
thoughts, and improving the remission rates. The
pharmacist may be actively involved in achieving the
goals through realization of various educational programs
for clarifying how important the therapy is. Development
of an individualized therapeutic plan in collaboration with
the psychiatrist and the affected patient and his family
members/caregivers, taking into consideration the
Table 4 Most Common Adverse Drug Reactions and Interactions Described for AD
Medication (INN) ADRs Interactions
Amitriptyline Arrhythmias, heart arrest, photo dermatitis,
constipation, dryness in mouth, sexual
dysfunctions





Nausea, vomiting, insomnia, dryness in
mouth, headache, hypotension, tremor, etc.
+MAO inhib.; +serotoninergic medications (triptans) ≤ SSS
+H. perforatum ≤ increased risk of ADRs; +NSAIDs; p.o.
anticoagulants ≤ risk of bleeding
Venlafaxine Dryness in mouth, headache, sweating,
nervousness, drowsiness, dizziness, etc.
+serotoninergic medications (triptans, SSRIs) ≤ SSS
Tianeptine Tachycardia, insomnia, headache, dryness in
mouth, myalgia, insomnia, etc.
+MAOinhibitors ≤ collapse, hyperthermia, convulsions
Notes: Some ADRs like nausea, diarrhea, and anxiety appear only in the beginning of the therapy. A consultation with a physician is required in cases of lack of improvement.
Tricyclic antidepressants (TCA) are not indicated in cases of recent myocardial infarction. Dose adjustment or switch to another medication in the case of lack of
effectiveness at a minimum 6 weeks is required.
Table 5 Some ADRs and Advice Given by Pharmacists for Overcoming Them
Adverse Drug Reactions (ADRs) Advice for Overcoming the ADRs
Dryness in mouth Application of artificial saliva products, sugar free gum, vitamin c tablets (short-term use in
order to prevent tooth erosion)
Antimuscarinic effects (blurred vision, sedation,
confusion, etc.) caused by TCA
A strict monitoring in elderly patients as well as taking medications at bed time in order to
prevent falls and fractures are recommended
Constipation Advice for regular healthy eating habits: more fiber, liquids, warm water in the morning,
abdominal massage, laxatives
Sedation Taking the medications at bed time; otherwise – dose reduction
Nausea Avoiding sweet, salty, or fatty food; taking the medicine after a meal, taking smaller portions
of food during the day
Insomnia Taking the medications in the morning
Sexual disturbances caused by SSRIs Dose reduction or change therapy; inclusion of sildenafil at a pinch
Hypertension caused by venlafaxine Blood pressure monitoring regularly; reduction of venlafaxine dosage; change the therapy
Tachycardia caused by TCA Dose reduction or change the therapy
Weight gain Dose reduction or change the therapy
Orthostatic hypotension The patient should avoid standing up abruptly, reduce caffeine intake, drink more water,
practice more physical exercise to strengthen the leg muscles
Headache Dose reduction or change the therapy
Photosensitization caused by TCA, SSRIs,
venlafaxine
Applying sun cream every 2 hours and avoiding sunbathing between 10 a.m. and 4 p.m.
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individual needs and preferences could significantly opti-
mize the therapy and improve the level of adherence.
Assuring Adherence and Assessment of Adherence
Level
Literature data shows that 56% of patients taking antidepres-
sants do not adhere to the prescribed therapy for different
reasons such as patients’ beliefs, side-effects, or cost.56 The
patient should be convinced that the disease is curable, the
therapy is based on the severity of the disease, and only strict
adherence, psychotherapy provided by a specialist, and suppor-
tof family and friends may lead to improvement and full
recovery. Assessment of the level of adherence might be
made during the regular patient’s visits on the basis of the num-
ber of dispensed packages and the number of executed pre-
scriptions, after a conversation with the patient regarding his
attitude toward the therapy and the therapeutic plan. A study
revealed that patients suggest several pharmacy services to
improve the adherence to antidepressants such as: a reminder
e-mail before each refill or a small group education session.10
Studies concluded that the pharmacists’ role is crucial for
improving the level of adherence to antidepressants.57,58
A systematic review found that pharmacist interventions
could be effective in improving the adherence level to antide-
pressants by15–27%.57 The individualized plan might be opti-
mized on the basis of the reported adverse drug reactions and
other DRPs so as to increase the level of adherence – for
example to take the medication in the evening in order to
avoid sedation during the day or to take the medication in the
morning so as to prevent insomnia.
Follow-Up and Reassessment of DRPs
Patients should be aware of the possible ADRs accompanying
AD therapy and be reminded to report all ADRs that occur.
Tracking the status and reassessment of DRPs is essential and
can be performed on the basis of a predefined plan at the
pharmacy during the next visit or through telephone calls.59
A published study highlights the importance of clinical phar-
macists as he/she is able to improve mild-to-moderate mental
health conditions, promote interdisciplinary collaboration
between various medical specialists, and to improve the pro-
cess of documentation and follow-up.60
Conclusion
Application of pharmaceutical care services for patients with
depression is effective and leads to condition improvement,
reduction of the side-effects, timely identification of and
the overcoming of potential or actual DRPs, and
improvement of patients’ quality-of-life. Collaboration
between psychiatrists, pharmacists, and the active inclusion
of the affected and their relatives in the therapy could
optimize and improve the complex care for patients with
depression and achieving the targeted therapeutic outcomes.
The current article could be used as an initial proposal
for creating a methodological guideline for providing phar-
maceutical care services for patients with depression.
A number of follow-up studies are needed to assess the
feasibility of implementing community-based pharmaceu-
tical care for patients with depression, the level of knowl-
edge of pharmacists on depression, the effect of
pharmaceutical care on this patient group, and the eco-
nomic benefits from the point of view of society.
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